文献速递类风湿关节炎脊柱关节炎系统性红斑狼疮

追逐靶点:2024年靶向治疗进展会议报告

Chasing the target: reports from the Advances in Targeted Therapies meeting, 2024.
PubMed 文献 · Ann Rheum Dis · 2025-04-15

第24届靶向治疗进展年会汇集逾100名国际风湿病学、免疫学及相关专科的临床医生和科研人员,分5个疾病专题组讨论未来5年最重要的未满足科学需求。各疾病组分别提出精确医学、疾病分型、新靶点及CAR T细胞疗法等方向,结论强调精确医学、难治性疾病新靶点及预防或治愈风湿病仍为最大未满足需求。

要点

  • 跨学科主题包括精确医学、疾病状态分类改进及靶点与相关疗法(含CAR T细胞疗法潜力)的进一步识别。
  • RA组强调缺乏精确医学、需更好生物标志物,以及靶向成纤维细胞疗法缺失和早期靶向成纤维细胞的潜在影响。
  • PsA组需更好定义疾病内型及对复杂和难治性(D2T)疾病分类,双特异性分子和联合治疗仍为高优先级。

核心结论

  • 在识别疾病内型及疾病进展或治疗应答生物标志物方面,通往精确医学的道路仍有许多未满足需求。
  • 对多数讨论的疾病,识别难治性或D2T疾病的新靶点和新疗法仍是强烈未满足需求。
  • 预防或治愈风湿病的能力仍是风湿病学终极未满足需求。

研究设计与样本

  • 第24届靶向治疗进展年会汇集逾100名国际风湿病学、免疫学及其他与免疫介导炎性疾病相关专科的临床医生和科研人员。
  • 会议设5个风湿病疾病专题讨论组,分别涵盖类风湿关节炎(RA)、银屑病关节炎(PsA)、中轴型脊柱关节炎(axSpA)、骨关节炎(OA)和系统性红斑狼疮(SLE)。
  • 每组专家被要求识别未来5年需解决的2至3项最重要总体性和疾病特异性科学未满足需求。

主要发现

  • 跨学科总体主题包括精确医学需求、疾病状态分类改进及靶点与相关疗法(含CAR T细胞疗法潜在作用)的进一步识别。
  • RA组强调缺乏精确医学和需要更好生物标志物,并讨论缺乏靶向成纤维细胞的疗法及早期靶向成纤维细胞的潜在影响这一未满足需求。
  • PsA组持续需要更好定义疾病内型和分类复杂及难治性(D2T)疾病患者,双特异性分子和联合治疗方法的开发仍为高优先级。
  • axSpA组需进一步评估非甾体抗炎药的疾病修饰特征,以及疾病中常见残留疼痛和疲劳的治疗。
  • OA组新治疗靶点仍为未满足需求,讨论组优先考虑可能带来创新治疗靶点的潜在实验策略,阐明负责或抑制修复的特定信号和靶细胞对开发靶向疗法至关重要。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The Advances in Targeted Therapies annual meeting brings together experts within the field of rheumatology and immunology to highlight and discuss the latest scientific developments and needs in the field. The objective is to highlight unmet scientific needs in the field of rheumatology. METHODS: The 24th annual Advances in Targeted Therapies meeting convened with more than 100 international clinicians and scientific researchers in rheumatology, immunology, and other specialities relating to all aspects of immune-mediated inflammatory diseases. During the meeting, we held 5 rheumatologic disease-specific discussion sections consisting of experts in each field. These groups included rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), osteoarthritis (OA), and systemic lupus erythematosus (SLE). In each group, experts were asked to identify the top 2 to 3 most important overarching and disease-specific scientific unmet needs to be addressed in the next 5 years. RESULTS: The overarching themes across disciplines included the need for precision medicine, improved classification of disease states, and the further identification of targets and associated therapies, including the potential role of chimeric antigen receptor (CAR) T cell therapies. Within RA, the group highlighted the lack of precision medicine and the need for better biomarkers. Further, the lack of targeted therapies against fibroblasts in RA was discussed, with the potential impact of targeting fibroblasts early in the disease as an unmet need. For PsA, there is a continued need for a better definition of disease endotypes and for the categorisation of those with complex and difficult-to-treat (D2T) diseases. The development of bispecific molecules and combination therapeutic approaches remain a high priority. For axSpA, the disease-modifying characteristics of nonsteroid anti-inflammatory drugs need further evaluation, as does the treatment of residual pain and fatigue frequently in the disease. In OA, new therapeutic targets remain an unmet need, and the discussion group prioritised potential experimental strategies that could lead to innovative therapeutic targets. Elucidating the specific signalling and target cells responsible for, or inhibiting, repair will be essential for developing targeted therapies. SLE experts emphasised the need to identify the most predictive biological contributions to disease progression in patients with early clinical precursors of SLE. The role of CAR T cell therapy must be further investigated, along with ancillary biologic studies (eg, immune system profiling) that provide critical insights into disease pathogenesis. Further, there is a need to determine the relationship of patient-relevant symptoms to the pathophysiology of SLE and identify new therapeutic targets for these symptoms. CONCLUSIONS: There remain many unmet needs on the road to precision medicine with regard to identifying disease endotypes and biomarkers for disease progression or therapeutic response. For most diseases discussed, a strong unmet need remains with regard to identifying new targets and therapies for those with refractory or D2T disease. The ability to prevent or cure rheumatic disease remains the ultimate unmet need in rheumatology.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Winthrop KL, Bathon J, Kerschbaumer A, et al. Chasing the target: reports from the Advances in Targeted Therapies meeting, 2024. Ann Rheum Dis. 2025. PMID: 40240265. doi:10.1016/j.ard.2025.02.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。